Table 3.

Major studies of CLDN18.2-targeting therapy.

Agent type	Trial number (NCT)	Phase	Cancer type	Agent	Experimental arm	Estimated enrollment
mAb	3505320	II	GC/EGJC	Zolbetuximab	1. Monotherapy 2. +FOLFOX 3. +Pembrolizumab 4. +FOLFOX + nivolumab	116
	3816163	II	PC	Zolbetuximab	+Gemcitabine + nab-paclitaxel	369
	4400383	I	Solid tumor	AB011	Monotherapy	228
	4671875	I	Solid tumor	MIL93	Monotherapy	197
	4683939	I/II	Solid tumor	BNT141	1. Monotherapy 2. +Gemcitabine + nab-paclitaxel	96
	5008445	I/II	Solid tumor	LM-102	1. Monotherapy 2. +Standard of care	265
	5065710	I/II	Solid tumor	ZL-1211	Monotherapy	162
BsAb	5482893	I	GC/GEJC, PC	PT886	Monotherapy	58
	4900818	I	Solid tumor	TJ033721 (TJ-CD4B)	Monotherapy	102
ADC	5043987	I	GC/GEJC, PC	CPO102	Monotherapy	72
	5001516	I/II	Solid tumor	LM302	Monotherapy	142
	5161390	I/II	Solid tumor	LM302	Monotherapy	128
	5994001	I/II	BTC	LM302	+Cardonilizumab	96
	5205850	I/IIa	Solid tumor	RC118	Monotherapy	135
	5867563	I	Solid tumor	TQB2103	Monotherapy	71
	4805307	I	Solid tumor	CMG901	Monotherapy	162
CAR-T cell	4404595	Ib/II	GC/GEJC, PC	CT041	Monotherapy	110
	4581473	Ib/II	GC/GEJC, PC	CT041	Monotherapy	192
	4467853	Ib/II	GC/GEJC	LCAR-C18S	Monotherapy	64
	4966143	Ib/II	PC	LY011	Monotherapy	30
	5472857	I	GC/GEJC, PC, OC	IMC002	Monotherapy	30
	5539430	I	EC, GC/GEJC, PC	LB1908	Monotherapy	56
	5620732	NA	GC, PC	CLDN18.2CAR-T	Monotherapy	20
	5952375	I	GC	XKDCT086	Monotherapy	9
BiTE	4260191	I	GC/GEJC	AMG 910	Monotherapy	70
	4856150	I	Solid tumor	Q-1802	Monotherapy	66
	6005493	I/II	EC, GC/GEJC, PC	AZD5863	Monotherapy	200
	5365581	I	GC/GEJC, PC	ASP2138	Monotherapy	240
Other	5009966	I	Solid tumor	LB4330 (specific bifunctional molecule)	Monotherapy	66